Schmid P, et al. - KEYNOTE-522: Phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early-stage high-risk triple-negative breast cancer. ESMO Congress 2019, abstract LBA8_PR.
Prognose HPV-geassocieerd orofarynxcarcinoom op basis van intratumoraal CD103
okt 2019 | Hoofd-halsoncologie